Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 3Thyroid Cancer, Papillary 1Parkinson Disease 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Immunoglobulin Light-chain Amyloidosis 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 8Iodine-131 5trametinib 3lenvatinib 3Thyrotropin Alfa 3Sunitinib 3Specimen Handling 3Sorafenib 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3selpercatinib 2dabrafenib 2cabozantinib 2X-Rays 2Vemurafenib 2Radiotherapy 2Everolimus 2AZD 6244 2vandetanib 1tremelimumab 1tovorafenib 1tanespimycin 1spartalizumab 1sargramostim 1romidepsin 1pembrolizumab 1omipalisib 1motesanib diphosphate 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Cancer, Papillary × Iodine-124 × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡